Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACT
Heparan sulfate (HS) binds growth factors, protein-degrading enzymes, and other bioactive proteins, and to regulate their activities. Many of these proteins have strong implications in human breast cancer. There is also evidence that cellular HS production itself exerts strong influences on tumorigenesis, exemplified by the fact that mutations of Ext1, the gene encoding an HS synthesizing enzyme, cause multiple bone tumors. Furthermore, the level of HS degrading activity correlates with the aggressiveness of the tumor. Despite these long-standing observations, much less is known about the mechanisms by which HS influences the malignant behavior of tumors in vivo. Also important is the fact that HS is produced not only by tumor cells themselves but also by stromal cells that constitute the tumor microenvironment. This project will conduct cohort study using genetic mouse models to address these key questions. The first year of this project was dedicated mainly to establish, expand, and intercross mouse models for generating experimental cohorts. We have also characterized the gene recombination pattern induced by the FSP1-Cre transgenic mouse, which will be used to manipulate the expression of HS in tumor stromal cells. (4) . These properties make the Ext1 gene as an excellent target for genetic disruption of heparan sulfate synthesis. This allows direct interpretation of the causal relationship between heparan sulfate and the resultant phenotype. Our primary objective is to obtain direct information regarding the role of heparan sulfate in breast cancer development and progression in the context of de novo mammary tumorigenesis models. An ancillary objective is to determine whether tumor cell-expressed heparan sulfate and stromal cell-expressed heparan sulfate exert distinct effects on the behavior of mammary tumors. We hypothesize that they have different effects on the growth and progression of mammary tumors. Through this project, we will define the role of heparan sulfate in breast cancer under the condition that mimics human breast cancer than ever before, thereby advancing our understanding of the role of heparan sulfate in breast cancer to the next level.
SUBJECT TERMS
Body Task 1. Acquisition of animal experiment approval.
Necessary approval for animal experiments was obtained on schedule.
Task. 2. Generation of animal cohorts for studies in Aim 1 (the role of tumor cell autonomous heparan sulfate in mammary tumor development and progression).
The original plan calls for the breeding of experimental animals for the MMTVCre/KFS2MT6-based tumorigenesis study during the first two years of the project. This part of the project has experienced a problem of low fertility of KFS2MT6 transgenic mice. We obtained KFS2MT6 transgenic mice (5) from Dr. Robert Oshima soon after the initiation of funding, and first attempted to expand the colony for the preparation of systematic crossbreeding with Ext1 flox (6) and MMTV-Cre mice. Unexpectedly, mating of KFS2MT6 + mice with wild-type (KFS2MT6 -) littermates exhibited low frequency of successful pregnancy. We also backcrossed KFS2MT6 + mice with unrelated, wild-type C57BL/6 mice with a similar result. We do not know what is the exact reason for this low efficiency of breeding. The KFS2MT6 transgenic mice obtained were young (~4 weeks old) and should be appropriate for breeding. During the same period, other mouse lines, including FSP1-Cre which is also used in this project, showed normal levels of breeding. It may be an intrinsic property of the line. As a possible remedy, we have obtained additional breeding pairs of KFS2MT6 transgenic mice to expand the basis for breeding.
As a result of this problem, the progress of this part of the project may experience a delay in subsequent years. Meanwhile, we have front loaded the breeding for Aim 2 to compensate the potential delay in Aim 1.
Task 3. Analysis of mammary tumors in Aim 1.
Because this part of the project is proposed to be conducted in the second and third years, it is not applicable to this report.
Task 4. Expression profiling of genes between Ext1 null and control tumors.
Task 5. Generation of animal cohorts for studies in Aim 2 (the role of stromally produced heparan sulfate in mammary tumor development and progression). The original plan calls for this part of the project to be conducted after Aim 1. However, to compensate the anticipated delay in Aim 1, we accelerated this part of the project as follows.
FSP1-Cre transgenic mice (7) were obtained from Dr. Eric Neilson of Vanderbilt University. The mice had white coat color, indicating that they still retain FVB background. Therefore, after conducting mandatory rederivation of the line, we proceeded to backcrossing to the C57BL/6 genetic background, in which all experiments are to be performed. Backcrossing for five generations has been completed ahead of the schedule, and intercrossing to produce experimental cohorts has recently been initiated. Unlike KFS2MT6 transgenic mice, we have not experienced any difficulties in breeding, although the average size of their litter has been slightly smaller than expected.
To characterize the recombination pattern driven by the FSP1-Cre transgene, we have crossed FSP1-Cre mice with Rosa26R Cre reporter mice (8) . One of the questions we wanted to examine with this validation study is how FSP1-Cremediated recombination occurs in developing embryos. As we discussed in the original application, a concern surrounding this study is that FSP1-Cre-mediated recombination may occur extensively in embryonic fibroblasts. Such early recombination could result in severe developmental defects or even embryonic lethality. Thus, we crossed Rosa26R reporter mice and FSP1-Cre mice, and compound mutant embryos were examined for the expression of β-galactosidase. As shown in Fig. 1 , recombination was detected in E12.5 embryos, but was highly restricted to the liver. Moreover, horizontal sections through the trunk demonstrated that recombination was restricted to the surface of the liver. The parenchyma of the liver was not stained for β-galactosidase. Thus FSP1-Cre does not induce gene recombination globally in embryonic fibroblasts, and it is rather unlikely that FSP1-Cre causes unwanted developmental defects that preclude the proposed experiments, although this needs to be further confirmed by examining the viability of FSP1-Cre;Ext1 flox/flox conditional mutants. In next litters, we will examine postnatal FSP1-Cre;Rosa26R mice to verify the recombination in fibroblasts in the mammary glands.
As discussed in the original application, if FSP1-Cre-mediated ablation of Ext1 results in embryonic or early postnatal lethality, or severe developmental defects in the mammary glands, we will need to employ an alternative approach based on an ex vivo grafting model as outlined in the original application. However, considering the result of the recombination pattern analysis, we are optimistic that the proposed in vivo study can be conducted as planned. 
Key Research Accomplishments
Establishing colonies of necessary mouse models
• Obtained KFS2MT6 transgenic mice.
• Obtained and rederived FSP1-Cre mice.
• Changed the genetic background of FSP1-Cre mice to the C57BL/6 background by backcrossing for 5 generations.
• Established genotyping protocols for the detection of the FSP1-Cre transgene.
• Established genotyping protocols for the detection of the KFS2MT6 transgene.
Breeding of experimental cohorts
• Expanded the colony of FSP1-Cre mice in the C57BL/6 background.
• Initiated crossing between FSP1-Cre and Ext1 flox mice.
Characterization of FSP1-Cre-mediated gene recombination patterns
• Bred FSP1-Cre;Rosa26R mice by crossing FSP1-Cre and Rosa26R reporter mice.
• Performed the analysis of gene recombination in FSP1-Cre;Rosa26R embryos by β-galactosidase assays.
• Analyzed the pattern of β-galactosidase staining in sections.
Development of analytic methods
• Developed an antigen retrieval protocol based on microwave irradiation for the sensitive detection of heparan sulfate in tissue sections.
Reportable Outcomes
• 
Conclusions
This is the first progress report of this IDEA award. The goal of the project is to obtain physiological evidence for the role of heparan sulfate in mammary tumor development and progression using conditional knockout mouse models. Because of the complexity of the breeding schemes necessary for producing triple compound mutant mice and their control counterparts, the large portion of the grant period is to be spent for crossbreeding of mice. Actual analyses and experiments are to be conducted toward the latter part of the funding period.
The first year has been spent mostly for setting up colonies of necessary mouse models and initial steps of crossbreeding to produce various compound mutant mice. Establishment and expansion of the colony of FSP1-Cre transgenic mice, the key model for Aim 2, have been going well and on schedule. To compensate the potential delay in Aim 1, we have front loaded breeding of compound mutants for Aim 2. We have also performed the analysis of FSP1-Cre-mediated spatial recombination patterns during embryonic development. FSP1-Cre does not induce extensive gene recombination in embryonic fibroblasts, which makes the possibility of embryonic lethality of FSP1-Cre;Ext1 flox/flox mice less likely. Overall, the progress in Aim 2 is ahead of schedule.
On the other hand, we have experienced the problem of inefficient breeding of KFS2MT6 transgenic mice, which would cause a delay in the progress of Aim 1. Breeding performance of laboratory mice can be affected by many factors (9) and it is often difficult to identify specific reasons. To remedy this problem, we will increase the number of breeding pairs and check and optimize housing conditions. We are confident that, although the drawback may incur some delay, we will be able to conduct the mouse cohort study as planned. Should this problem persist during the second year, we will turn to the alternative ex vivo model as outlined in the original application. Methodologies: Our experimental tool is the conditional Ext1 allele. The key glycosyltransferase for the HS biosynthetic process is the GlcNAc/GlcA copolymerase encoded by the Ext1 gene. Genetic and biochemical studies have established that EXT1 is absolutely essential for HS biosynthesis. We have created loxP-modified Ext1 allele, from which conditional Ext1 knockout mice can be generated by crossing with Cre transgenic mice targeted to various tissue and cell types. In this project, conditional ablation of the Ext1 gene will be combined with polyoma middle T antigen (PyMT)-dependent de novo mammary tumorigenesis models. We will produce MMTV-Cre;KFS2MT6;Ext1 flox/flox animals (KFS2MT6 is a PyMT transgene that is activated by Cre-mediated excision of the STOP cassette). MMTV-Cre will activate PyMT expression and disrupt Ext1 concurrently in the mammary epithelium. Therefore, this system will allow us to examine specifically the role of tumor cell autonomous HS. We will also examine PyMT-induced mammary tumorigenesis in the HS-deficient stromal environment. For this, Ext1 will be disrupted specifically in stromal fibroblasts, without interfering HS synthesis in tumor cells, using the FSP1-Cre transgene. This experiment will allow us to determine the role of stromal cell-derived HS in tumor progression. In both experiments, mammary tumor progression will be analyzed in terms of growth, angiogenesis, invasion, and metastasis. Microarray analysis will be performed on tumor RNAs to gain insight into the difference in intracellular signaling between Ext1 null and control backgrounds.
Results to Date:
We have completed backcrossing all necessary lines to C57BL/6 and are currently breeding experimental and control groups for the tumor analyses.
Conclusions:
Considering its clear implication in tumor growth and progression, HS is an emerging therapeutic target in breast cancer.
Yet our current concept on the role of HS in tumor development is derived mostly from the observations obtained from non-physiological experimental models. This project would have a direct impact on this issue by defining the physiological role of HS in mammary tumor development and progression. 
